18:31 , Nov 18, 2016 |  BC Week In Review  |  Clinical News

Biosimilar teriparatide regulatory update

EMA's CHMP recommended approval of Terrosa/Movymia, a biosimilar of osteoporosis drug Forsteo teriparatide from Eli Lilly and Co. (NYSE:LLY, Indianapolis, Ind.). The biosimilar is under review to treat osteoporosis in postmenopausal women and in men...